gemtuzumab ozogamicin

(redirected from Gemtuzumab)

gemtuzumab ozogamicin

 [gem-too´zoo-mab″ o″zo-gah-mi´sin]
a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.
Mentioned in ?
References in periodicals archive ?
This means that treatment with gemtuzumab ozogamicin would only get rid of the problematic MDSC wall, leaving the beneficial immune cells relatively untouched.
the purpose of the framework agreement is to be able to supply the hospital pharmacies with amgros~ stakeholders with the drug mylotarg (gemtuzumab ozogamicin).
Pre-transplant risk factors of SOS include liver dysfunction (hepatitis, fibrosis, cirrhosis, etc.), hepatic metastases, history of liver radiotherapy, hepatotoxic agents (including herbal remedies, gemtuzumab ozogamicin, melphalan, cytosine arabinoside, and cyclophosphamide), infectious attacks, iron overload, history of stem cell transplantation, and advanced age.
However, the use of ADCs for cancer therapy has achieved considerable success in recent years after the introduction of four clinically approved ADCs such as Brentuximab vedotin (6,7), Trastuzumab emtansine (8-11), Inotuzumab ozogamicin (12) and Gemtuzumab ozogamicin (12,13) used for the treatment of patients with lymphoma (HL and ALL), HER2-positive, CD22-positive AML and CD33-positive ALL cancers, respectively.
IDH1 Ivosidenib Approved Adults with relapsed or refractory AML associated with IDH1 mutation FT-2102 and others Investigational BCL2 Venetoclax Investigational TET2 Vitamin C and Approved (*) AML with low blast count (*) hypomethylating agents CD33 Gemtuzumab ozogamicin Approved Newly diagnosed CD33-positive AML MDM2 Idasanutlin Investigational (*) US Food and Drug Administration (FDA) approval status (#) Hypomethylating agent (azacitidine) approved for low blast count AML in the US
Regulators in the EU have approved Pfizer's (NYSE: PFE) Mylotarg (gemtuzumab ozogamicin) as a treatment for a certain subset of patients with acute myeloid leukaemia (AML), Pharma Times reported on Wednesday.
Pfizer received FDA approval for Mylotarg[TM] (Gemtuzumab Ozogamicin), in 2000 the only approved antibody-drug conjugate for newly diagnosed and relapsed or refractory CD33-positive acute myeloid leukemia.
Food and Drug Administration has approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.1 MYLOTARG is the first therapy with an indication that includes pediatric AML.
Examples include rituximab in CD[20.sup.+] B-cell lymphomas, the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin, and the anti-CD123 antibody CSL362 in refractory AMLs; the anti-CD38 antibody daratumumab in plasma cell myeloma; and CD19-chimeric antigen receptor T cells in B-ALLs.
Gemtuzumab ozogamicin (GO) is a cluster of difference (CD33)-specific antibody and the first immunotherapy agent that has been tested for the treatment of AML.[sup][48] Several clinical trials have confirmed its antileukemic effect in adult AML.[sup][49] With an OS of about 30%, GO was approved for the treatment of CD33-positive AML during the first relapse in patients >60 years of age who were not considered for cytotoxic chemotherapy.[sup][50]
At the time the first antibody-drug conjugate (ADC), gemtuzumab ozogamicin (Mylotarg[R]) that targets CD33, had already been approved for the treatment of amyloid myeloid leukemia.